It is argued that metastatic competence, therapy resistance, and immune evasion can be viewed as functional outputs of remembered plasticity rather than solely as consequences of a contemporaneous mesenchymal phenotype, positioning memory-bearing states as an important target for future therapeutic strategies.
Abstract
Epithelial–mesenchymal transition (EMT) is increasingly recognized as a dynamic, plastic process that equips tumor cells with invasive capacity, stress tolerance, stem-like features, and adaptability, contributing to metastasis, therapeutic failure, and immune escape. Accumulating evidence indicates that these effects can outlast the inducing signal: tumor cells may retain molecular and functional traces of prior EMT exposure, biasing future cell-state behavior. This Review terms this phenomenon EMT memory. We propose EMT memory as a conceptual framework distinguishing it from EMT induction and maintenance through its persistence after signal withdrawal, its capacity to alter future cellular responsiveness, and, in its strongest form, its transmissibility across cell division. DNA methylation and chromatin-state remodeling emerge as the most plausible core substrates, reinforced by histone dynamics, chromatin remodelers, and noncoding RNA networks that stabilize post-EMT states. Temporal concepts including hysteresis, reversibility windows, and partial EMT stabilization clarify when transient plasticity becomes durably encoded, helping explain why highly aggressive tumor cells are often not fully mesenchymal yet remain strongly metastatic, drug tolerant, and immune evasive. We argue that metastatic competence, therapy resistance, and immune evasion can be viewed as functional outputs of remembered plasticity rather than solely as consequences of a contemporaneous mesenchymal phenotype. If transient EMT can be consolidated into persistent adaptive states, therapeutically relevant vulnerabilities may lie not only in EMT-inducing pathways, but also in the mechanisms that encode, reinforce, and preserve EMT memory—positioning memory-bearing states as an important target for future therapeutic strategies.
Tumor plasticity and microenvironmental heterogeneity are established as an integrated, evolving system that fuels metastasis and limits durable treatment responses.
G. Dagar, M. Dagar, Ashna Gupta et al.· MedComm· 0 citations
The conceptual boundaries and operational criteria for identifying OnF in CRC are discussed, its regulatory mechanisms, plasticity-associated phenotypes, and translational relevance are examined, and the importance of distinguishing direct evidence of OnF from evidence of related plasticity mechanisms is emphasized.
Hao-Yu Wang, Song-Hao Liu, Ming-Xuan Zhang et al.· Frontiers in Oncology· 0 citations
The clinical translation of EMT-directed interventions faces steep methodological hurdles, primarily driven by unverified causal dynamics and unresolved therapeutic safety profiles, and will require dynamic, multi-pronged strategies tailored to specific carcinoma cell states and spatial niches.
Xuecong Wang, C. Zhang, Yi Zhao et al.· Cancer Metastasis Review· 0 citations
This review evaluating how the antagonistic interplay between Polycomb and Trithorax complexes, chromatin modifier activity, and enhancer reprogramming affects lineage identity and enables multi-lineage plasticity in cancer underscores epigenetic deregulation as a primary driver of lineage plasticity and intratumoral heterogeneity.
Ezgi Boyvatlı, Burcu Akman, E. Bağırsakçı et al.· FEBS Letters· 0 citations
Unraveling the intricate mechanisms of EMT activation in cancer will contribute to the advancement of personalized medicine and the design of more effective treatments against metastatic disease and pave the way for advancements in personalized medicine and improved treatment strategies for patients affected by EMT-related conditions.
Vafa Meftahpour, T. C. Dakal, Jarek Maciaczyk et al.· Signal Transduction and Targ...· 0 citations
By integrating diverse mesenchymal transition processes under a unified conceptual framework, this review positions mesenchymal drift as a unifying axis of stromal-immune reprogramming in prostate cancer and underscores its significance for next-generation therapeutic strategies.
Zijia Zhang, Feifan Liu, Shuze Liu et al.· iScience· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.